Dr. Chloé Rossi

Pathologist · Universitätsklinikum Heidelberg · Germany (DE) · Oncology

Tier 3STK-0003GoodOwner MSL JWJames Whitfield

Data minimisation

Consent status: Recorded. The name shown may be a pseudonym. Contact details, personal identifiers and remuneration fields are hidden for your role; only scientific-profile fields needed for engagement planning are displayed.

Specialty: Thoracic oncology
Disease interests: NSCLC, SCLC
Scientific interests: Elderly patientsBrain metastases
Engagement preference: In person
Advisory boards: 1
Publications: 9
Source system: Veeva CRM
Data quality: Good

Engagement plan

Cadence target for Tier 3: 1 per year (assumption)

Last engaged: 16 Jan 2026 (242 days ago)
Next planned contact: 16 Jan 2027
Last 6 months vs target: 0%
0 of 1 expected engagements

Insights from this stakeholder (1)

INS-0070Sequencing after progression
17 Jan 2026 · Competitor activity
HighClosed

Engagement history (1)

All engagements including drafts, newest first

Date	Type	Format	MSL	Product	Topics	Insights	Flags	Status
16 Jan 2026	Payer / HTA meeting	Phone	James Whitfield	Vantrexa	Sequencing after progression	1	—	Reviewed	ENG-0047

Timeline

16 Jan 2026
Payer / HTA meeting
Sequencing after progression

Related stakeholders (8)

Universitätsklinikum Heidelberg

Dr. Andrea Castellano
Thoracic medical oncologist
Tier 3
Dr. William Abbott
Radiation oncologist
Tier 3
Dr. Sven Eriksen
Academic nephrologist
Tier 2
Dr. Benedikt Vogel
Community nephrologist
Tier 1
Dr. Benedikt Xu
Academic nephrologist
Tier 2
Dr. Tomoko Xu
Primary care physician
Tier 1
Dr. Andrea Ivanova
Allergist
Tier 3
Dr. Quentin Zimmermann
Allergist
Tier 2